Cisplatin plus norcantharidin alter the expression of TGF-β1/Smads signaling pathway in hepatocellular carcinoma

Abstract

PU RPOSE: To investigate the effects of ci splatin plus norcantharidin on transforming growth factor (TGF)-β1/ Smads signaling pathway in hepatocellular carcinoma cells. METHODS: Hepatocellular carcinoma cells (Hep3B) were divided into four groups: control group, cis platin 2.0 μg/ml group, norcantharidin 10 μg/ml group, and cisplatin 2.0 μg/ml plus norcantharidin 10 μg/ml group. All cells were incubated for 24 hours. Cells proliferation was assessed using cell counting kit-8. R elative mRNA expression of TGF-β1, Smad4 and Smad7 were assessed by quan titative RT-PCR. Protein expression of TGF-β1 and Smad4 were investigated by western blotting. RESULTS: Cispl atin, norcantharidin and cisplatin plus norcantharidin signifi cantly inhibited the proliferation of cells , signifi cantly attenuated both the mRNA and p rotein expression of TGF-β 1 and S mad7, and signifi cantly up-regulated the mRNA and protein expression of Smad4 in Hep3B (all p < 0.05), and cisplatin plus norcantharidin exhibited powerful effects than cisplatin and norcantharidin. CONCLUSIONS: Cisplatin, norcantharidin and cisplatin plus norcantharidin can si gnifi cantly alter the expression of TGF-β1/Smads signaling pathway and inhibit the proliferation of Hep3B cells. Cisplatin plus norcantharidin exhibited powerful effe cts than cisplatin and norcantharidin (Fig. 4, Ref. 23). Text i n PDF www.elis.sk.

Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities

“…These are incomparable advantages over many traditional anticancer drugs. In addition, NCTD has a synergistic effect with a variety of anticancer drugs, such as cisplatin and gefitinib [53,54].…”

Tanshinone IIA alters the transforming growth factor-β1/Smads pathway in angiotensin II-treated rat hepatic stellate cells

“…Membranes were incubated with anti-rat primary antibodies (ab92486, ab40759, ab216428, and ab6276) from Abcam PLC (Cambridge, UK), followed by IgG-horseradish peroxidase secondary antibodies to detect TGF-β1, Smad4, Smad7, and β-actin expression. 10 Chemiluminescence was detected with an ECL Western Blotting Detection Kit (Amersham, Little Chalfont, UK) and quantified with a Box gel imaging system (Syngene, Frederick, MD, USA) and Image Lab 3.0 software (Bio-Rad). β-actin protein (Abcam PLC) was used as an internal control.…”

Identification and Profiling of Environmental Chemicals That Inhibit the TGFβ/SMAD Signaling Pathway

“…To investigate the effect of potential SBE-bla antagonists on inhibition of downstream SMAD3 phosphorylation, intracellular pSMAD3 (Ser 423/425) level was measured using HTRF technology. HepG2 cells were co-treated with 0.15 ng/mL TGFβ1 and test compound for 1 h. As shown in Figure 4A, pSMAD3 level was decreased upon treatment of dasatinib 38 or cantharidin, 39 which are known inhibitors in TGFβ1-induced SMAD3 phosphorylation. The novel SBE antagonists identified here reduced TGFβ1-induced pSMAD3 level with potency similar to dasatinib.…”